An observational study in Short Bowel Syndrome, sponsored by Medical University of Vienna. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.
Sponsored by Medical University of Vienna · Observational
A retrospective analysis was performed using data of patients suffering from non-malignant SBS-IF. They were treated with teduglutide in a multidisciplinary SBS-IF program at a single university medical center between June 2016 and June 2020.
149 studies on the registry are indexed under Short Bowel Syndrome; 25 are open to participants now.
This study's enrollment of 17 is below the median of 53 across 36 observational studies indexed under Short Bowel Syndrome.
Browse Short Bowel Syndrome studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 177 are open to participants now.
Counted across the registry records on this site, refreshed daily.
SBS-IF patients receiving teduglutide for at least 6 months
Exclusion Criteria:
effect of teduglutide on intestinal rehabilitation
enteral autonomy
percentage of patients reaching complete discontinuation of parenteral support
Time frame: at least 6 months of teduglutide treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna